Pharming Group NV (PHARM) - Financial and Strategic SWOT Analysis Review

June 2021 | 54 pages | ID: P898B95386DEN
GlobalData

Abstracts

Pharming Group NV (PHARM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Pharming Group NV (Pharming) develops precision medicines and innovative protein replacement therapies for the treatment of rare diseases and unmet medical needs. The company’s marketed product includes, Ruconest (conestat alfa), a recombinant human C1 inhibitor is used for the treatment of acute hereditary angioedema (HAE) and has been approved in the US, the UK, Europe, Israel, and South Korea. Its product pipeline consists of rhC1INH for the treatment of pre-eclampsia, COVID-19 and acute kidney injury; leniolisib for treatment of activated phosphoinositide 3-kinase delta syndrome (APDS); a-Glucosidase for the treatment of pompe and fabry’s disease. The company markets its products through own sales force and network of distributors and partners. Pharming is headquartered in Leiden, the Netherlands.

Pharming Group NV Key Recent Developments

May 19,2021: Pharming Reports on Annual General Meeting of Shareholders
Apr 06,2021: Pharming Group announces the publication of its 2020 Annual Report and convenes its 2021 AGM
Mar 31,2021: Pharming Group reports financial results for the first quarter of 2021
Mar 23,2021: Pharming Group announces the intention to nominate three Non-Executive Directors to the Board of Directors
Mar 23,2021: Pharming Group announces the intention to nominate three NonExecutive Directors to the Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Pharming Group NV - Key Facts
Pharming Group NV - Key Employees
Pharming Group NV - Key Employee Biographies
Pharming Group NV - Major Products and Services
Pharming Group NV - History
Pharming Group NV - Company Statement
Pharming Group NV - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Pharming Group NV - Business Description
Geographical Segment: Europe
Performance
Geographical Segment: Rest of the world (RoW)
Performance
Geographical Segment: The US
Performance
R&D Overview
Pharming Group NV - Corporate Strategy
Pharming Group NV - SWOT Analysis
SWOT Analysis - Overview
Pharming Group NV - Strengths
Pharming Group NV - Weaknesses
Pharming Group NV - Opportunities
Pharming Group NV - Threats
Pharming Group NV - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Pharming Group NV, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 19, 2021: Pharming Reports on Annual General Meeting of Shareholders
Apr 06, 2021: Pharming Group announces the publication of its 2020 Annual Report and convenes its 2021 AGM
Mar 31, 2021: Pharming Group reports financial results for the first quarter of 2021
Mar 23, 2021: Pharming Group announces the intention to nominate three Non-Executive Directors to the Board of Directors
Mar 23, 2021: Pharming Group announces the intention to nominate three NonExecutive Directors to the Board of Directors
Mar 16, 2021: Pharming Group to present at 31st Annual Oppenheimer Healthcare Conference
Mar 04, 2021: Pharming Group reports financial results for full year 2020
Mar 04, 2021: Pharming reports financial results for full year 2020
Mar 02, 2021: Pharming Group, in collaboration with Invitae , launches genetic testing program 'navigateAPDS' in US and Canada
Nov 09, 2020: Pharming appoints Jeroen Wakkerman as Chief Financial Officer

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Pharming Group NV, Key Facts
Pharming Group NV, Key Employees
Pharming Group NV, Key Employee Biographies
Pharming Group NV, Major Products and Services
Pharming Group NV, History
Pharming Group NV, Subsidiaries
Pharming Group NV, Key Competitors
Pharming Group NV, Ratios based on current share price
Pharming Group NV, Annual Ratios
Pharming Group NV, Annual Ratios (Cont...1)
Pharming Group NV, Annual Ratios (Cont...2)
Pharming Group NV, Interim Ratios
Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Pharming Group NV, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Pharming Group NV, Performance Chart (2016 - 2020)
Pharming Group NV, Ratio Charts
Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Pharming Group NV, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021